Posted on: 15th October 2015
XORTX Pharma Corp. – a company focused on the development of drugs to treat orphan and non-orphan kidney diseases – is pleased to announce the Issuance of a U.S. Patent No. 9,155,740, entitled “COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES”. A patent with claims to the use of all uric..More
Posted on: 28th November 2014
XORTX Pharma Corp. is pleased to announce the appointment of Mr. Bruce Rowlands to the XORTX Board of Directors, effective November 28, 2014. This appointment increases the XORTX Board of Directors to four members including Mr. Robert Reider, Mr. Bruce Rowlands, Dr. Alan Moore and Dr. Allen Davidoff – President and CEO. Mr. Rowlands has..More
Posted on: 25th November 2014
http://www.marketwired.com/press-release/bradmer-pharmaceuticals-inc-announces-proposed-reverse-take-over-transaction-with-xortx-tsx-venture-bmr.h-1969569.htm
Posted on: 19th July 2013
XORTX Pharma Corp. is pleased to announce the election of the Board of Directors, completed July 19, 2013.Election of the Board of Directors was completed by unanimous shareholder agreement and resulted in the re-election of Dr. Alan Moore and Dr. Allen Davidoff to the Board of Directors, as well as the addition of Mr. Robert..More
Posted on: 29th November 2012
XORTX Pharma Corp. wishes to congratulate Dr. Beth Soletsky and Dr Daniel Fieg on the successful completion of their phase II clinical trial in adolescent hypertension entitled “Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents” and publication of results in the prestigious journal Hypertension, 2012;60:1148. The trial, a randomized, double blind, placebo controlled study, was..More
Posted on: 15th October 2012
XORTX Pharma Corp. today announced the completion of a first round of financing. Dr. Allen Davidoff stated, “The company has taken a strong step forward with the completion of this first series of financing of XORTX Pharma Corp. The combination of novel patents that protect this new area of drug therapy, strong non-clinical and positive phase II..More
Posted on: 24th August 2012
XORTX Pharma Corp. today announced the formation of a privately held Pharmaceutical Development Company built upon novel patents (intellectual property) in the fields of hypertension, insulin resistance, metabolic syndrome and diabetes prevention. The novel patents protect the use of all uric acid lowering agents (approved and in development) for the treatment of the aforementioned disease..More